The registration of physical signals has long been an important part of cardiological diagnostics. Current technology makes it possible to send large amounts of data to remote locations. Solutions that enable diagnosis and treatment without direct contact with patients are of enormous value, especially during the COVID-19 outbreak, as the elderly require special protection. The most important examples of telemonitoring in cardiology include the use of implanted devices such as pacemakers and defibrillators, as well as wearable sensors and data processing units. The arrythmia detection and monitoring patients with heart failure are the best studied in the clinical setting, although in many instances we still lack clear evidence of benefits of remote approaches vs. standard care. Monitoring for ischemia is less well studied. It is clear however that the economic and organizational gains of telemonitoring for healthcare systems are substantial. Both patients and healthcare professionals have expressed an enormous demand for the further development of such technologies. In addition to these subjects, in this paper we also describe the safety concerns associated with transmitting and storing potentially sensitive personal data.

Graphene is a novel carbon-based material with unique crystal nanostructure and extraordinary physical and chemical properties. Several biomedical applications of graphene and graphene-derived materials have been proposed. Its antimicrobial properties might be useful in all areas of medicine where antiseptics are required. On the other hand, the safe limits of graphene concentration for human cells have not been clearly established yet. The possibility to attach various chemically active groups to the basic lattice structure allows researchers to build graphene-based sensors for detecting biochemical molecules (and ultimately - selected cells). Sensors for physical signals, such as cardiac electrical activity, have also been proposed. The unique nanostructure of the material and the resulting physical properties (mechanical strength, elasticity and large surface area) make it a very promising material for scaffolds used in tissue regeneration. Several studies have investigated the potential advantages of a graphene coating for endovascular implants, such as stents or valves. Most of them indicate an advantage of graphene coating over other currently available solutions in terms of better hemocompatibility and facilitating endothelialization. Many of the results published so far are from in vitro studies. Promising as they might be, more data, preferably from experiments on more sophisticated animal models, must be obtained before any valid conclusions as to potential uses of graphene in medicine can be drawn.

Background: With modern diagnostic tools, incidence ischemia with no obstructive coronary atherosclerosis (INOCA) and heart failure with preserved ejection fraction (HFpEF) are found to be much higher than previously believed, and—as they lead to adverse cardiovascular outcomes—their causes and development are subjects of ongoing research. There is growing evidence that coronary microvascular dysfunction might be the underlying cause of both INOCA and HFpEF. Methods: In 65 patients with effort angina but no obstructive coronary artery disease, the index of microvascular resistance and coronary flow reserve were measured invasively in the LAD. The echocardiographic parameters, including left atrial strain, left ventricular strain, and indices of left ventricular diastolic dysfunction, were compared between two groups of patients: those with normal coronary microcirculation parameters and those with impaired coronary microvascular function. Results: Patients with coronary microvascular dysfunction had higher a E/E′ index than those with normal microvessel reactivity. This finding was further confirmed by ROC analysis. The groups did not differ significantly in values of other echocardiographic parameters, including the left ventricular and left atrial strain. The prevalence of classical cardiovascular risk factors was similar in both groups. Conclusions: The coexistence of impaired coronary microvascular function with moderately elevated left ventricular filling pressures might correspond to the co-development of early stages of coronary microvascular dysfunction and HFpEF.

Percutaneous Coronary Intervention (PCI) is a treatment method that involves reopening narrowed arteries with a balloon catheter that delivers a cylindrical, mesh-shaped implant device to the site of the stenosis. Currently, by applying a coating to a bare metal stent (BMS) surface to improve biocompatibility, the main risks after PCI, such as restenosis and thrombosis, are reduced while maintaining the basic requirements for the mechanical behavior of the stent itself. In this work, for the first time, the development and optimization process of the spatial structure of the Co-Cr stent (L-605) with a graphene-based coating using cold-wall chemical vapor deposition (CW-CVD) to ensure uniform coverage of the implant was attempted. The CW-CVD process allows the coating of 3D structures, minimizing thermal stress on the surrounding equipment and allowing the deposition of coatings on temperature-sensitive materials. It produces uniform and high-purity films with control over the thickness and composition. The reduced heating of the chamber walls minimizes unwanted reactions, leading to fewer impurities in the final coating. The graphene layers obtained using Raman spectroscopy at different parameters of the CW-CVD process were verified, their properties were investigated, and the functional mechanical behavior of the studied graphene-covered stent was confirmed. In vitro, graphene-coated stents promoted rapid endothelial cell repopulation, an advantage over gold-standard drug-eluting stents delaying re-endothelialization. Also, full-range biocompatibility studies on potential allergic, irritation, toxicological, and pyrogenic reactions of new material in vivo on small animal models demonstrated excellent biocompatibility of the graphene-coated stents.

The immune responses to both SARS-CoV-2 infection and vaccines are of key importance in prevention efforts. In April and May 2020, 703 study participants tested for COVID-19 by PCR tests were registered. In June and July 2020, they were examined for the presence of SARS-CoV-2 S1/S2 IgG. From October 2020 to January 2021, those among the study population with COVID-19 confirmed by PCR tests were registered, and the same group of participants was invited to be examined again for the presence of SARS-CoV-2 antibodies. In June 2020, antibodies were detected in only 88% of those who had PCR-confirmed COVID-19 in April–May 2020, which suggests that a significant proportion of persons in the Polish population do not produce antibodies after contact with SARS-CoV-2 antigens or rapidly lose them and reach levels below the lab detection limit. The levels of IgG class anti-SARS-CoV-2 antibodies were significantly lower among people who previously had COVID-19 than for those who had received COVID-19 vaccination, which confirms the high immunogenicity of the vaccines against COVID-19 in the Polish population. The study confirms that a detectable level of IgG class anti-SARS-CoV-2 antibodies cannot be considered a reliable marker of the presence and strength of COVID-19 immunity preventing individuals from acquiring SARS-CoV-2 infection.

Coronary drug-eluting stents (DESs) are the current clinical standard, yet delayed endothelialization remains a critical challenge. Graphene-based coatings have emerged as promising cardiovascular biomaterials due to their favorable hemocompatibility and ability to support endothelial cell growth. In this study, we evaluated the in vivo performance of graphene-coated stents (GCSs) compared with commercial sirolimus-eluting stents in a Polish White swine model (n = 10). Stents were implanted into major coronary branches, with follow-up at 30 and 90 days using quantitative coronary angiography (QCA), optical coherence tomography (OCT), and cryogenic scanning electron microscopy (cryo-SEM). No systemic toxicity, mortality, thrombotic events, or ischemic complications were observed during the study period. QCA demonstrated no significant differences in percent diameter stenosis between GCSs and DESs at either 30 days (12.3 ± 6.1% vs. 8.6 ± 5.8%, p = 0.2782) or 90 days (18.3 ± 10.5% vs. 9.6 ± 6.6%, p = 0.1074). OCT analysis confirmed comparable lumen and neointimal parameters between groups, while demonstrating a favorable, although non-significant, trend toward a lower percentage of uncovered struts in GCSs. Cryo-SEM imaging demonstrated stable tissue integration and a preserved healing response surrounding GCSs. Collectively, these findings indicate that GCSs are safe and biocompatible and demonstrate mid-term vascular performance comparable to clinically used DES platforms. The presented results support further investigation of graphene-based coatings as potential surface-modification strategies for coronary stents.